Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GTG to co-develop cancer product with pharma firm
The tie up allows GTG to utilize some of its intellectual property and expertise for the development of specific and novel genetic oncology profiling systems to target chemotherapy
The tie up allows GTG to utilize some of its intellectual property and expertise for the development of specific and novel genetic oncology profiling systems to target chemotherapy
The partnership is intended to leverage both companies’ strengths, matching Pfizer‘s global capabilities in developing medicines with Shanghai Pharmaceutical’s capabilities and reach in the China market. The companies
AIC246 is currently is in Phase IIb trial. AiCuris CEO Rubsamen-Schaeff said the orphan drug status will also support the company in the development of AIC246 as it
Gilead‘s net income was $651.14m for the first quarter 2011, or $0.08 per diluted share, compared to net income of $854.9m, or $0.92 per diluted share, for the
Labeling and marketing materials for the affected products claim that they can prevent infection from other disease-causing agents. In addition, the labeling of some of the firms hand
Wellmune WGP is a product of the US biotechnology company Biothera. Hormel Health Labs said the products, available in Lemonade, Pomegranate-Cherry and Raspberry-Green Tea flavors, provide an immune
The agreement is a second transaction between Altacor and Ophthalmopharma in which Altacor assumes responsibilities for their entire portfolio of ophthalmic products covering development, IP and commercialisation of
Wedgewood Pharmacy makes customized prescription medications when FDA approved manufactured drugs like Cytarabine which are not available or when human and animal patients need a special dosage-form or
ARGENT gene expression regulation technology is expected to add a valuable tool to Regenx’s NAV platform by providing control of gene expression and the potential for safety and
Through the collaboration with University of Minnesota and James Cloyd, Neurelis has also partnered with experts in clinical research of the nasal delivery of benzodiazepines. The company expects